Interior web banner image

Briumvi in NYC

What is Briumvi?

Briumvi (ublituximab-xiiy) is a prescription medication indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

How Does Briumvi Work?

Briumvi is a monoclonal antibody therapy that works by depleting the B-cell population. It binds to the CD20 antigen found on the B-cells (which is a type of white blood cell), and removes them from circulating in the body. In MS, B-cells play a role in brain and spinal cord damage.

This medication is administered by intravenous (IV) infusion by a medical professional. The administration schedule of Briumvi consists of a day one infusion of 150mg administered in four hours, a day 15 infusion of 450mg administered in one hour, followed by 450mg infusions every 24 weeks administered in one hour.